Combination immunotherapy for advanced bladder cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug, CA-4948, combined with pembrolizumab (Keytruda) for people with advanced bladder cancer that grew after prior immunotherapy. The goal is to see if this combination can help when standard treatments stop working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have bladder cancer that has spread or cannot be removed by surgery.
- You are 18 years or older.
- Your cancer progressed after at least 6 weeks of treatment with a PD-1 or PD-L1 inhibitor (like pembrolizumab).
- You have also had either platinum-based chemotherapy or enfortumab vedotin (Padcev).
- You are generally able to care for yourself (ECOG score 0-2).
- Your blood counts and organ function are within acceptable ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (N-803, pembrolizumab, and enfortumab vedotin) for advanced bladder cancer that has not been treated with systemic therapy. The goal is to see if this combination can shrink or control the cancer and improve outcomes.
This trial tests a two-drug combination (pembrolizumab and enfortumab vedotin) followed by maintenance pembrolizumab for people with advanced bladder cancer that has not been treated before. The goal is to see if this approach helps control the cancer for longer.
This trial tests a new drug combination (pembrolizumab and sacituzumab govitecan) against standard treatment for advanced bladder cancer that has spread or cannot be removed by surgery. It's for people who have already tried an immunotherapy drug like pembrolizumab and another drug called enfortumab vedotin.
This trial tests two drugs, enfortumab vedotin and pembrolizumab, given before surgery to remove the bladder or ureter in people with advanced bladder or upper urinary tract cancer that has spread to lymph nodes or other organs. The goal is to see if this treatment helps shrink the cancer and improves outcomes.
This study tests adding new treatments to a standard therapy (enfortumab vedotin and pembrolizumab) for people with advanced bladder cancer that hasn't been treated before. It aims to find out if these combinations are safe and work better.
This trial tests a combination of three drugs for advanced bladder cancer (including cancer of the renal pelvis or ureter) that has not been treated before. The goal is to see if the combination is safe and effective.
Hear when a new Metastatic Urothelial Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.